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Objective: To assess the cellular DNA status of epithelial ovarian cancer cells for clinical stage identification and its effect on 
survival. Methods: Sixty-two patients treated by primary surgery and six courses of platinum-based chemotherapy were 
enrolled. The surgical stage was analyzed in correlation with DNA ploidy, S-phase fraction and DNA index. DNA analysis 
was performed via image cytometry. Results: From the 62 cases, 38 were International Federation of Gynecology and 
Obstetrics (Fédération Internationale de Gynécologie et d’Obstétrique, FIGO) stage I and II, 24 – stage III and IV. In the DNA 
histograms obtained, the DNA index ranged from 0.85 to 3.02. Sixteen were classified as diploid and 46 as aneuploid 
(18 multiploid). S-phase fraction ranged from 9.8 to 51%. The aneuploid cells with DNA content above 5C ranged from 0.0 
to 77.2%. Patients diagnosed with FIGO III and IV (vs. I and II) were 3.3 times more likely to die. Only in FIGO stage I and II 
the survival differed significantly for the different groups of ploidy. The risk of death for the multiploid (vs. diploid) group 
is 6.4 times and for aneuploid (vs. diploid) 2.3 times. Overall survival was better in the group with low DNA index. The low 
percentage compared with a high percentage of 5C cells ploidy groups showed association with mortality. The death hazard 
for the S-phase >33 median group is 4.9 times the hazard in relation to the S-phase <33. Conclusions: DNA ploidy, DNA 
index, S-phase, and 5C cells are important prognosticators for epithelial ovarian cancer mainly in early stages.
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Cel: Ocena statusu DNA komórek nabłonkowego raka jajnika w różnych stopniach zaawansowania klinicznego i jego wpływ 
na przeżycie. Metoda: Do badania zakwalifikowano 62 pacjentki leczone operacyjnie i za pomocą chemioterapii opartej na 
platynie (6 kursów). Stopień zaawansowania klinicznego nowotworu analizowano w odniesieniu do ploidalności DNA, frakcji 
fazy S oraz indeksu DNA. Analizę DNA przeprowadzono z zastosowaniem cytometrii obrazowej. Wyniki: Spośród 
62 pacjentek 38 zakwalifikowano jako stopień zaawansowania I i II, natomiast 24 – jako stopień III i IV wg FIGO (International 
Federation of Gynecology and Obstetrics). W otrzymanych histogramach DNA indeks DNA wynosił 0,85–3,02. Szesnaście 
przypadków raka zaklasyfikowano jako diploidalne, natomiast 46 – jako aneuploidalne (18 multiploidalnych). Frakcja fazy S 
mieściła się w przedziale 9,8–51%. Odsetek komórek aneuploidalnych z zawartością DNA powyżej poziomu 5C wynosił 
0,0–77,2%. Ryzyko śmierci było 3,3-krotnie większe w przypadku pacjentek z chorobą w stopniu zaawansowania FIGO III i IV 
(w porównaniu z I i II). Jedynie w przypadku stopni zaawansowania FIGO I i II odnotowano istotnie różnice w przeżywalności 
między poszczególnymi grupami ploidalności. Ryzyko śmierci było 6,4-krotnie większe w przypadku multiploidalności 
i 2,3-krotnie większe w przypadku aneuploidalności (w porównaniu z diploidalnością). Dłuższe przeżycie ogólne odnotowano 
w grupie o niskim indeksie DNA. Wykazano związek między niskim odsetkiem komórek 5C, w porównaniu z wysokim 
odsetkiem tych komórek w grupach poliploidalnych, a śmiertelnością. Ryzyko śmierci było 4,9-krotnie większe w grupie 
z medianą liczby komórek w fazie S >33 w porównaniu z medianą liczby komórek w fazie S <33. Wnioski: Ploidalność DNA, 
indeks DNA, faza S oraz obecność komórek 5C to ważne czynniki prognostyczne u pacjentek z nabłonkowym rakiem jajnika, 
głównie we wczesnym stadium.
Słowa kluczowe: zawartość DNA, nabłonkowy rak jajnika, rokowanie
Abstract
Streszczenie
António Tomé1, Irene Leal2, Carlos Palmeiras3,  




© Curr Gynecol Oncol 2018, 16 (1), p. 3–10
DOI: 10.15557/CGO.2018.0001
António Tomé, Irene Leal, Carlos Palmeiras, Eduarda Matos, João Amado, Miguel Abreu, Carlos Lopes
4
CURR GYNECOL ONCOL 2018, 16 (1), p. 3–10DOI: 10.15557/CGO.2018.0001
INTRODUCTION
Epithelial ovarian cancer (EOC) is the fifth most com-mon female malignancy worldwide; more than 70% of patients are diagnosed with advanced disease, and 
5-year survival rates are less than 30% with approximately 
141,000 new cases and 106,000 deaths annually(1,2).
The main prognostic factors considered in the evaluation of 
ovarian cancer are International Federation of Gynecology 
and Obstetrics (Fédération Internationale de Gynécologie 
et d’Obstétrique, FIGO) stage, the presence of a residual 
tumor, histological grade, histological type, and age(3–6). 
Most of them have significant shortcomings due to their 
subjectivity and lack of reproducibility, and low prognos-
tic power. Therefore, the search for an additional prognos-
tic factor that can be more objectively measured and with 
better reproducibility has been intensified. One of the more 
promising candidates in this regard is DNA content mea-
surement(7–26). While there have been reports on a correla-
tion between ploidy pattern and clinical pathological find-
ings and therapeutic results, some other reports have shown 
no correlation between these factors(12). Thus, the results are 
variable and no definite conclusions may be drawn.
DNA aneuploidy, which indicates a state with an abnor-
mal DNA and chromosome content, has been identified 
or mentioned in various human cancers. This parameter 
is considered to be an important biological and prognostic 
variable in ovarian cancer(17,18,22,23).
Numerous studies showed a  close association between 
tumor ploidy and outcome (prognosis). Among patients 
with advanced ovarian cancer, those with diploid tumors 
have a significantly better survival than those with aneu-
ploid tumors(8,11,24).
A multivariate analysis has shown that ploidy is a pow-
erful and independent prognosis variable. These findings 
have been confirmed in most studies and ploidy/DNA 
index (DI) is a prognostic value in patients with both early- 
and advanced-stage ovarian tumors as well as in those with 
borderline ovarian tumors(25,26).
In the case of ovarian carcinoma, some authors have reported 
an objective assessment of grading by cytophotometry, 
achieving a good correlation between the histological grade 
of ovarian tumors and DNA content(7,10). Borderline and 
early-stage ovarian tumors had a significantly lower number 
of aneuploid cells, whereas advanced-stage invariant tumors 
had a significantly high number of aneuploid cells.
Image cytometry studies report that it is possible to deter-
mine the ploidy level in a given tumor using the parameters 
obtained from DNA histogram, assessed based on Feulgen-
stained nuclei. The percentage of aneuploid cells with DNA 
content above 5C (5CER) is another ploidy parameter and 
is important in assessing ovarian cancer aggressiveness, 
being a reliable biomarker in the risk assessment for this 
type of tumor(23–26).
This aim of the study was to evaluate the value of DNA 
content (DNA ploidy/DI/S-phase, 5CER), using image 
cytometry, for predicting long-term survival of patients 
with epithelial ovarian cancer.
MATERIAL AND METHODS
The study comprised 62 patients with ovarian cancer diag-
nosis who were treated from January 1982 to December 
1997 in the Hospital Geral de Santo Antonio, Porto, 
Portugal.
All patients were treated by multidisciplinary medical surgi-
cal teams and following international protocols (defined by 
the corresponding FIGO stage), and were subjected to che-
motherapy based on platinum when indicated.
All patients had invasive tumors. All histological sections 
were reviewed by a reference pathologist and histological 
classifications were performed using the criteria defined by 
the World Health Organization (WHO). The tumors were 
graded according to the WHO histological grading system 
as grade 1, 2 or 3. Clinical information was available for 
all patients (date of initial diagnosis, surgical stage, tumor 
grade, initial tumor volume, residual tumor volume, histo-
logical differentiation, age, treatment, follow-up) and the 
date of death confirmed. The study ended in June 2006.
Quantification of DNA content
Ovary sections of 6 µm were cut from paraffin-embed-
ded blocks, deparaffinized and rehydrated. The slides were 
then Feulgen-stained with CAS DNA Staining Kit (Cell 
Analysis Systems, Elmhurst, IL), according to the manu-
facturer’s instructions. Briefly, the sections were hydrolyzed 
in 5N HCL solution for 60 minutes and then transferred 
to the CAS DNA stain solution for 1 hour. After staining, 
the slides were placed in three consecutive CAS rinse solu-
tions for 30 seconds, 5 minutes and 10 minutes, respec-
tively. The slides were then washed in deionized water and 
placed in acid alcohol solution for 5 minutes. Finally, the 
slides were dehydrated and mounted. The Feulgen reaction 
produced a blue staining of nuclear DNA reflecting stoi-
chiometric binding of the stain to the DNA. CAS staining 
of rat hepatocytes was used as a control slide. These cells, 
having a known quantity of DNA, were used as the exter-
nal control, allowing for instrument calibration prior to 
DNA image analysis. The nuclear DNA content of cells was 
measured with the CAS 200 image analysis system (Cell 
Analysis Systems, Elmhurst, IL). The quantitative DNA 
analysis system is well suited for DNA content evaluation in 
human cells. However, if the diploid value of the specimens 
studied is different from human diploid cells, an “internal 
control” must be used, such as lymphocytes. For this reason 
in each tumor in addition to a minimum of 130 non-over-
lapping and well preserved ovarian nuclei, 20 to 30 normal 
lymphocytes were measured. The resultant DNA histo-
grams were analyzed by previously described methods(12). 
For each tumor, G0/G1 peak was visually identified, mean, 
standard deviation (SD) and coefficient of variation (CV) 
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values were calculated. The DI describes the relative DNA 
content of the study population and was defined as the 
ratio of the mean DNA content of the ovarian G0/G1 peak 
divided by the mean DNA content of the resting diploid 
lymphocyte G0/G1 peak. The 5CER was also evaluated and 
defined as the percentage of cells with DNA values above 
5n. Tumors were considered aneuploid only if a separate 
G0/G1 peak was distinguishable on the histogram and its 
DI was different from the reference lymphocyte population 
by more than 2 SD, mean standard deviation. A DNA dip-
loid tumor showed a single distinct G0/G1 peak with a DI 
within 2 SD from the control lymphocytes and usually with 
less than 1% of 5CER.
Statistical analysis
The probability for the risk of death after diagnosis was cal-
culated according to the Kaplan–Meier method. The influ-
ence of concomitant covariates on the cumulative probabil-
ity rates was analysed using the proportional hazard model 
described by Cox.
RESULTS
All tumors were analyzed by image cytometry for ploidy, 
the percentage of cells in S-phase, and 5CER (5C).
Evaluable image cytometry DNA histograms were obtained 
from all 62 patients with ovarian carcinoma. 
The DI ranged from 0.85 to 3.02. Sixteen (25.8%) ovar-
ian carcinomas were classified as diploid and 46 (74.2%) as 
aneuploid including 18 multiploid tumors.
The S-phase fraction (SPF) ranged from 9.8 to 51% with 
a median value of 33%. This value was not observed in 
20 patients.
The percentage of 5C ranged from 0.0 to 77.2% with 
a median value of 3.15%.
Survival by FIGO
FIGO staging was performed in 62 patients. For the pur-
pose of survival analysis, tumors were classified as early 
stage (FIGO I + FIGO II) or advanced stage (FIGO III and 
FIGO IV).
Patients diagnosed with FIGO III and IV were 3.3 times 
more likely to die than patients with FIGO I  and II 
(95% confidence interval, CI: 1.667–6.564).
Survival for types of ploidy 
by stage of FIGO
It was shown (Fig. 1) that only in FIGO I and II the sur-
vival differed significantly for the different groups of ploidy:
I + II: df: 2 Log-rank: 7.450 p-value = 0.024 
Breslow: 8.484 p-value = 0.014
III + IV: df: 2 Log-rank: 0.610 p-value = 0.737 
Breslow: 0.528 p-value = 0.768
The hazard for the multiploid group is 6.4 times the 
risk of death in relation to the diploid group (95% CI: 
1.283–32.171) with statistical significance (p = 0.024).
The hazard for the aneuploid is 2.3 times the risk of death 
for the diploid, without significance (95% CI: 0.474–11.015).
Survival for DNA median value
Considering the test in each stratum (Fig. 2) it can be seen 
that for FIGO I and II the survival does not differ signifi-
cantly between the groups of DNA, but the curves are well 
separated:
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I + II: df: 2 Log-rank: 7.450 p-value = 0.024 Breslow: 8.484 p-value = 0.014







Fig. 1. Epithelial ovarian cancer: early and advanced stages and cumulative survival by ploidy groups
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I + II: Log-rank: χ2 = 1.477 df = 1 p-value = 0.22
 Breslow: χ2 = 1.895 p-value = 0.17
III + IV: Log-rank: χ2 = 0.455 df = 1 p-value = 0.50
 Breslow: χ2 = 0.182 df = 1 p-value = 0.67
Overall, the survival is higher in the group with low DNA 
index (Tab. 1) compared with the group with high DNA 
index, however with no statistical significance.
The analysis in each stratum shows that in FIGO I and II the 
survival does not differ significantly between the groups of 
the 5C percentage (Fig. 3), but the curves are well separated:
I + II: Log-rank: χ2 = 2.414 df = 1 p-value = 0.12 
 Breslow: χ2 = 3.58 df = 1 p-value = 0.06
III + IV: Log-rank: χ2 = 0.331 df = 1 p-value = 0.56
 Breslow: χ2 = 0.252 df = 1 p-value = 0.62
Results for the low percentage of 5C cells ploidy groups 
(≤3.15) compared with high percentage of 5C cells (>3.15) 
(Tab. 2 and Fig. 4) showed association with mortality.
After approximately five years, the survival was higher in 
patients with S-phase ≤33 (Fig. 4).
I + II: Log-rank: χ2 = 4.795 df = 1 p-value = 0.03
 Breslow: χ2 = 4.837 df = 1 p-value = 0.03
III + IV: Log-rank: χ2 = 0.013 df = 1 p-value = 0.91
 Breslow: χ2 = 0.04 df = 1 p-value = 0.84
The hazard for the S-phase >33 (median) group is 
4.9 times the risk in relation to the S-phase <33 (95% CI: 
1.009–23.572) with statistical significance (p = 0.049).
The clinical stage was the strongest covariate, with FIGO III 
and IV patients being, 3 times more likely to die than 
patients with FIGO I and II (95% CI: 1.571–5.610).
DISCUSSION
Ovarian cancer is the leading cause of death from gyne-
cologic malignancies in the Western world. The majority 
of patients are diagnosed with advanced stage disease pri-
marily due to peritoneal seeding from the primary tumor, 
which leads to peritoneal carcinomatosis without specific 
signs or symptoms. In addition, screening strategies have 
not yet been proven effective in increasing the number 
of patients diagnosed at earlier stages(2,27). Approximately 
one-third of the presently studied cases were localized 
(early stage disease); the prognosis for these women was 
much better than for patients with FIGO stage III or IV 
(two-third of the cases). Combined therapy with sur-
gery followed by chemotherapy has been the cornerstone 
of therapeutic management in the past two decades. 
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Fig. 2. Epithelial ovarian cancer: cumulative survival by DNA index groups
FIGO N % censored Median 95% median confidence interval Upper quartile






















Per5C – percentage of 5C.
Log rank: χ2 = 2.102, df = 1, p-value = 0.15; Breslow: χ2 = 3.557, df = 1, p-value = 0.06.
Tab. 1. FIGO I and II cumulative survival of 5C cells groups
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Substantial progress has been made and although an 
increasing number of patients live longer with their dis-
ease, the majority of patients with advanced ovarian can-
cer are not cured. The prognosis in ovarian cancer is dis-
couraging compared to other malignancies of the female 
genital tract. Despite aggressive surgery and intensified 
chemotherapy, the outcome of patients with stage III and 
IV is poor. Relevant prognostic factors are necessary to 
estimate the course of the disease and to define biolog-
ically similar subgroups for the analysis of therapeutic 
efficacy(10,28). The prognosis of patients with ovarian can-
cer was suggested to depend on individual tumor charac-
teristics rather than on therapy(10,13). Many studies have 
been devoted to finding “prognostic factors,” and numer-
ous features have been described that can help predict 
the prognosis of early and advanced ovarian cancer with 
varying degrees of accuracy. One of the most promis-
ing candidates in this regard is DNA content measure-
ment. In the early 1970s, DNA ploidy in ovarian cancer 
was suggested to be of prognostic impact. It has been con-
firmed in most studies that DNA content (DNA ploidy/
S-phase/DI/5C) is of prognostic value in patients with 
both early and advanced stage ovarian tumors as well 
as in those with borderline ovarian tumors(15,17,18,25,29–31), 
results that we could associate with recent EGFL7 expres-
sion studies(32).
In this study, unlike in the great majority of other stud-
ies, the percentage of early stage (I–II) cancers was 
higher than the advanced stage cancers. This is due to 
the fact that many of these cases were referred to hospital. 
Fig. 3. Epithelial ovarian cancer cumulative survival: low vs. high percentage of 5C cells groups
Most of the patients were diagnosed in routine gyneco-
logic exams or by other specialists after imaging exams 
for different clinical indications. In fact, nowadays, an 
increased number ovarian cancers are diagnosed at early 
stages, also as a result of improved primary care provided 
by general practitioners. Nevertheless, we still diagnose 
a  great number of advanced stage cancers, although 
this number is decreasing. In our study, 38 cases were 
FIGO stages I and II and 24 cases were stage III and IV. 
Concerning the survival rate, groups I/II and III/IV were 
formed. In the first group, the survival rate was 3.3 times 
higher when compared with the second one. The stage is 
considered the most important prognostic factor in epi-
thelial ovarian cancer. There are subgroups of patients 
with significant differences in survival rates: patients 
with surgically documented early disease (localized) 
versus patients with advanced disseminated disease. 
The 5-year survival rate is about 70–90% for the first 
groups and 10–18% for the second one, confirming the 
results of different studies(27,32).
The survival rate in relation to ploidy and stages showed 
that significant differences were present only in FIGO 
stages I and II, for the different ploidy groups. The group 
of aneuploid tumors was most frequent. The frequency 
of aneuploidy increases, among other things, with age, 
advanced disease, histologic type(3). As in other studies, 
the non-diploid tumors were more frequent in advanced 
stage tumors. The survival rate for diploid tumors was 
4–6  times greater when compared with multiploid 
tumors. So, in the same stage, the DNA ploidy showed 
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to be an inadequate prognostic factor, with lower sur-
vival rates for the non-diploid tumors than the diploid 
tumors. Tropé et al. showed that in FIGO stage I DNA 
ploidy was a significant independent prognostic factor for 
disease-free survival with p < 0.0001(22). It was reported 
that a DNA index of more than 1.3 was the most impor-
tant prognostic factor in multivariate analysis(29), in con-
trast to the report of Friedlander et al., who found that in 
the group of DNA-periploid tumors only the exact DNA-
diploid tumors are relevant for a better prognosis(8,9). 
In this investigation, tumors with DNA index less than 
1.4 had better survival rate compared with tumors with 
a DNA index higher than 1.4, although no statistical dif-
ference was observed in this study. Tumors with a higher 
DNA index have a more aggressive biological nature(33–37). 
There is a correlation between DNA ploidy/DI and other 
factors, such as histological grade, with higher aggressive-
ness in high grade tumors. Aneuploid tumors were more 
often poorly differentiated than euploid tumors.
Multiploid tumors differ in survival rate, with lower 
survival versus diploid tumors. Patients with aneuploid 
tumors with a high percentage of 5C cells (multiploid) 
had significantly poorer 2 and 5-year corrected surviv-
als than patients with diploid tumors. In this study, the 
tumors with 5C ploidy lower than 3.15 showed associa-
tion with better survival rates when compared to tumors 
with an elevated percentage of 5C cells, with advanced 
stage cancers having a higher number of 5C cells. The cell 
kinetic data are also important indicators of tumor 
aggressiveness and treatment response. Tumor growth is 
determined by a balance between tumor cell proliferation 
and cell loss, and proliferation is, in turn, dependent on 
the fraction of proliferating cells and cell cycling time. 
Determination of ovarian tumor proliferating activity 
will be of prognostic value. Several methods exist for 
this purpose, including Ki-67 expression and cytomet-
ric SPF. DNA ploidy and SPF showed a significant corre-
lation with survival in malignant tumor, while SPF > 10% 
showed significant correlation with decreased survival in 
stage I and II cancer(29,30,38). There are some data to sug-
gest that the SPF may be of prognostic significance in 
ovarian cancer, but there are also a number of studies 
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Log rank: χ2 = 2.095, df =1, p-value = 0.15; Breslow: χ2 = 4.38, df =1, p-value = 0.036.
Tab. 2. FIGO I + II and FIGO III + IV cumulative survival of S-phase groups
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that contradict these results(25). Coley et al. published 
that tumors with a high SPF showed shorter median sur-
vival compared to those with a low SPF(13). The aneuploid 
tumor also showed the highest SPFs, which was indica-
tive of a high proliferation rate(13). In Norwegian Radium 
Hospital series, the diploid tumors had a significantly 
lower SPF than the aneuploid tumors. One of the reasons 
why the results from previous works have been contro-
versial is probably the tumor heterogeneity(30,39). In our 
study patients with S-phase ≤33 had greater survival rate 
when compared with patients with S-phase >33, with 
a risk of survival less than 4.9 showing statistical signifi-
cance in the present study.
CONCLUSION
In this study we can conclude that all the variables that 
differed in mortality occurred in patients with early stage 
cancers (I and II), although these are increasingly detected 
with higher sensibility and specificity of screening using 
CA-125 plus HE4 and biomarkers(2,27,28). In these stages, the 
multiploid tumors with elevated S-phase showed a predic-
tive value for higher risk of mortality.
The DNA content is an important prognostic factor for epi-
thelial ovarian cancer. Other important factors like resid-
ual disease, age, histology type and grade were not evalu-
ated as well as other imunohistochemical factors including 
ARID1A, CA-125 and its new cut-off of 18 U/mL(32,40). 
The study of these other factors would contribute to a bet-
ter understanding of this cancer.
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